Raise the acetylcholine that is left
(±)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one · C24H29NO3 · MW 379.49 g/mol · CAS 120014-06-4 · Aricept · ChEMBL CHEMBL502
Donepezil (Aricept). A reversible, mixed competitive/noncompetitive acetylcholinesterase inhibitor that raises synaptic ACh in whatever cholinergic terminals Alzheimer's has not yet destroyed. Modest cognitive benefit, dose-limited by nausea, diarrhea, vivid dreams, and vagal bradycardia / syncope. It is the pharmacological opposite of scopolamine #066: one blocks muscarinic receptors, the other floods them with leftover transmitter. PDB 6O4W is a real human AChE–donepezil crystal.
Donepezil spans AChE's gorge from the catalytic anionic site to the peripheral site — the classic dual-binding pose in 6O4W (human AChE, Gerlits et al.). ACh lingers; nicotinic and muscarinic receptors see more agonist. Benefit is symptomatic and small on average; it does not rebuild cortex. Memantine (#043) is often combined: different receptor, different kinetics.
Because you are globally boosting ACh, you buy the cholinergic toxidrome-lite: nausea, diarrhea, cramps, insomnia or vivid dreams (especially if dosed at night), bradycardia, heart block, syncope, and peptic-ulcer risk with NSAIDs. Anticholinergics (including many bladder and allergy drugs) pharmacologically cancel it.
Benzylpiperidine in the CAS, dimethoxyindanone toward the PAS. Real crystal, 6O4W.
Whatever nucleus basalis terminals remain. No new neurons.
Bradycardia, AV block, syncope — check pulse, caution with β-blockers and sick sinus.
Nausea, diarrhea, anorexia, weight loss. The usual titration-limiter.
Both contribute; inhibitors can raise levels. t½ ~70 h means slow approach to steady state (~2 weeks).
Diphenhydramine, oxybutynin, scopolamine, many TCAs — opposite pharmacology, worse cognition.
Well absorbed; Tmax ~3–4 h; t½ ~70 h; steady state ~15 days. CYP2D6 and CYP3A4; glucuronides. 5 mg → 10 mg (and 23 mg ER) titration is GI-limited.
Scopolamine and diphenhydramine are delirium drugs in the elderly; donepezil is trying to do the reverse. Memantine is an NMDA uncompetitive blocker with different kinetics — combination is common and mechanistically coherent. Donepezil is not a stimulant, not a cure, and overnight 'Aricept dreams' are a cholinergic REM story, not a haunting.
Donepezil is a relatively rigid piperidine–indanone. It pays little ΔS_conf to occupy a
pre-organized AChE gorge that evolved to swallow ACh. The crystal (6O4W) shows the Shannon collapse:
gorge waters out, aromatic lining packed against the benzyl and indanone. High affinity from shape
complementarity more than a single covalent warhead — reversible, mixed kinetics.
Overdose looks like a cholinergic toxidrome. Everyday harm is bradycardia, falls, and GI loss.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
AChE
acetylcholinesterase
|
IC50 ≈ 6 – 20 nM
reversible gorge inhibitor
|
Inhibitor | |
|
BChE
butyrylcholinesterase
|
weaker
less selective than AChE
|
Weaker | |
|
nAChR / mAChR
direct
|
no (indirect via ACh)
not scopolamine
|
Indirect | |
|
NMDA
memantine site
|
no
combination is two drugs
|
None |